Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1280013-68-4

C26H39N3O3 is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1280013-68-4 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1280013-68-4 Structure

  • Basic information

    1. Product Name: C26H39N3O3
    2. Synonyms: C26H39N3O3
    3. CAS NO:1280013-68-4
    4. Molecular Formula:
    5. Molecular Weight: 441.614
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1280013-68-4.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: C26H39N3O3(CAS DataBase Reference)
    10. NIST Chemistry Reference: C26H39N3O3(1280013-68-4)
    11. EPA Substance Registry System: C26H39N3O3(1280013-68-4)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1280013-68-4(Hazardous Substances Data)

1280013-68-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1280013-68-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,8,0,0,1 and 3 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1280013-68:
(9*1)+(8*2)+(7*8)+(6*0)+(5*0)+(4*1)+(3*3)+(2*6)+(1*8)=114
114 % 10 = 4
So 1280013-68-4 is a valid CAS Registry Number.

1280013-68-4Relevant articles and documents

Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5- dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: A highly potent orally available CCR5 selective antagonist

Nishizawa, Rena,Nishiyama, Toshihiko,Hisaichi, Katsuya,Minamoto, Chiaki,Murota, Masayuki,Takaoka, Yoshikazu,Nakai, Hisao,Tada, Hideaki,Sagawa, Kenji,Shibayama, Shiro,Fukushima, Daikichi,Maeda, Kenji,Mitsuya, Hiroaki

, p. 4028 - 4042 (2011/08/21)

Based on the original spirodiketopiperazine design framework, further optimization of an orally available CCR5 antagonist was undertaken. Structural hybridization of the hydroxylated analog 4 derived from one of the oxidative metabolites and the new orally available non-hydroxylated benzoic acid analog 5 resulted in another potent orally available CCR5 antagonist 6a as a clinical candidate. Full details of a structure-activity relationship (SAR) study and ADME properties are presented.

Spirodiketopiperazine-based CCR5 antagonist: Discovery of an antiretroviral drug candidate

Nishizawa, Rena,Nishiyama, Toshihiko,Hisaichi, Katsuya,Minamoto, Chiaki,Matsunaga, Naoki,Takaoka, Yoshikazu,Nakai, Hisao,Jenkinson, Stephen,Kazmierski, Wieslaw M.,Tada, Hideaki,Sagawa, Kenji,Shibayama, Shiro,Fukushima, Daikichi,Maeda, Kenji,Mitsuya, Hiroaki

, p. 1141 - 1145 (2011/04/16)

Following the discovery that hydroxylated derivative 3 (Fig. 1) was one of the oxidative metabolites of the original lead 1, it was found that hydroxylated compound 4 possesses higher in vitro anti-HIV potency than the corresponding non-hydroxylated compo

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1280013-68-4